Insights
Insights From Our Experts
Articles
Inspection Readiness: Building a Continuous Evidence Model
Stop treating regulatory inspections like a fire drill. Discover how to build a continuous, AI-powered evidence model that keeps your quality system permanently audit-ready. When an FDA or regulatory inspection is announced, what happens next in your organization? …
AI in Quality Systems: From Dashboard Reporting to Predictive Compliance Posture
Quality teams are drowning in data. Between deviations, CAPAs, complaints, audits, and supplier metrics, the volume of information is staggering. Yet, many quality leaders are still relying on retrospective dashboards that only explain what went wrong after the…
Evidence Hierarchies, PICO Coverage and Real-World Data: Emerging Insights from Early JCAs
As Europe shifts to a PICO-centric model, redefining your Real-World Data (RWD) strategy is no longer optional. It’s essential for market access. The landscape of European Health Technology Assessment (HTA) is evolving. Emerging insights from early Joint Clinical Assessments (JCAs)…
Reimagining AI’s Role in Medical Information Contact Centers
Is Your AI Built for a Retail Desk or a Medical Information Contact Center? Artificial intelligence promises unprecedented efficiency in contact center operations, but the Medical Information Contact Center (MICC) is not a standard customer service…
A Guide to Establish Medical Information
Building a Medical Information (MI) function from the ground up is one of the most complex hurdles for emerging biopharma companies preparing for launch. Yet it remains the most crucial. Navigating compliance requirements, selecting technology, and building contact center operations while…
Affordability Is No Longer a Copay Problem. It’s an Access Strategy.
Turn affordability into a powerful driver of patient access, therapy adoption, and Gross-to-Net performance with a smarter, connected access strategy.
From Quality Metrics to Compliance Signals: What Should Executives Actually Be Measuring?
True quality system maturity requires a fundamental shift: moving from retrospective quality metrics to predictive compliance signals. Instead of just tracking volume, executives must analyze deviation recurrence, CAPA effectiveness, and hidden patterns across their eQMS. By leveraging specialized AI…
Choosing the Right Indirect Treatment Comparison When Navigating Cross-Trial Heterogeneity
Navigate the Complexity of Modern Evidence Synthesis In modern health economics and outcomes research (HEOR), selecting the right Indirect Treatment Comparison (ITC) is no longer just a technical detail but a critical driver of regulatory success, HTA submissions,…
The Industry Doesn’t Have an Access Collaboration Problem. It Has an Accountability Problem.
Who should own market access? Today, market access is no longer a solo responsibility. Access outcomes are shaped by decisions made across nearly every corporate function—from R&D to regulatory to trade and channel to field reimbursement. Yet many organizations still operate in silos, acquiring “access debt.” Every decision can create reimbursement, affordability, or distribution…
Rethinking Quality Systems Compliance in the Age of AI
For pharmaceutical and medical device organizations, the baseline for regulatory trust has fundamentally shifted. Compliance is no longer proved by a shelf of well-written procedures or confident explanations during an inspection. Rather, it is demonstrated by a system’s ability…